Verrica Pharmaceuticals Inc. (VRCA) reported preliminary positive results from Part 2 of Phase 2 clinical trial studying VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. All patients treated with VP-315 had a reduction in tumor size with an overall reduction of tumor size in all subjects of 86%. VP-315 was well tolerated with no reported treatment-related serious adverse events, the company said.
Ted White, CEO of Verrica, said: "We are encouraged by our preliminary results, which we believe support the use of VP-315 as a first line therapy for use in both a primary and neoadjuvant setting. We believe VP-315 has the potential to be a multi-billion dollar commercial opportunity for Verrica."
The company expects genomic and T-cell data in the first quarter of 2025 and plans to request an End-of-Phase 2 meeting with the FDA to determine next steps for the development of VP-315 for the treatment of BCC in the first half of 2025.
Shares of Verrica Pharmaceuticals are up 23% in pre-market trade on Wednesday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.